Kisunla 17.5 mg/mL
donanemab-azbt · INJECTION, SOLUTION · Eli Lilly and Company
No Recall History
Plain English
Kisunla is a injection, solution containing donanemab-azbt at 17.5 mg/mL, taken intravenous. Manufactured by Eli Lilly and Company.
Key Facts
- Brand Name
- Kisunla
- Generic Name
- donanemab-azbt
- NDC Code (Product)
0002-9401- Manufacturer
- Eli Lilly and Company
- Strength
- 17.5 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761248
- Marketing Start
- 07/02/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is Kisunla used for?
Kisunla contains donanemab-azbt. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is Kisunla a controlled substance?
Kisunla is not classified as a controlled substance by the DEA.
What is the generic name for Kisunla?
The generic name for Kisunla is donanemab-azbt. There are no other listed brand versions of donanemab-azbt.
What is the NDC code for Kisunla 17.5 mg/mL?
The NDC (National Drug Code) for Kisunla 17.5 mg/mL is 0002-9401, listed by Eli Lilly and Company.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)